Amgen, AstraZeneca report phase 3 results for Tezspire in eosinophilic esophagitis
Amgen, AstraZeneca report phase 3 results for Tezspire in eosinophilic esophagitis Seeking Alpha
Covered in this story
Analyst targets on Amgen
- Cantor Fitzgerald: $432 → $440 by Oct 2027 · neutral via MarketBeat
- Wells Fargo: $432 → $430 by Oct 2027 · equal weight via MarketBeat
- Scotiabank: $432 → $500 by Oct 2027 · outperform via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 9 Oct 2026.
Summary aggregated from Seeking Alpha's public RSS feed. The full reporting belongs to Seeking Alpha — please read it on their site.